Ataxia, Cerebellar, Cayman Type (ATCAY) Peptide
-
- Target See all ATCAY products
- ATCAY (Ataxia, Cerebellar, Cayman Type (ATCAY))
- Peptide Type
- Synthetic
- Origin
- Mammalian
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
- Sequence
- LIPMEHVQIP DCVLQYEEER LKARRESARP QPEFVLPRSE EKPEVAPVEN
- Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of ATCAY antibody,
Alternative Names: ATCAY control peptide, ATCAY antibody Blocking Peptide, Anti-ATCAY Blocking Peptide, ataxia, cerebellar, Cayman type Blocking Peptide, BNIP-H Blocking Peptide, CLAC Blocking Peptide, KIAA1872 Blocking Peptide
-
-
- Application Notes
- Optimal conditions should be determined by the investigator
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handling Advice
- Avoid repeated freeze/thaw cycles.
- Storage
- -20 °C
- Storage Comment
- Store at -20 °C long term.
-
- Target
- ATCAY (Ataxia, Cerebellar, Cayman Type (ATCAY))
- Synonyms
- BNIP-H Peptide, CLAC Peptide, 3322401A10Rik Peptide, BB077577 Peptide, hes Peptide, ji Peptide, ATCAY, caytaxin Peptide, ataxia, cerebellar, Cayman type Peptide, ATCAY Peptide, Atcay Peptide
- Background
- This gene encodes a neuron-restricted protein that contains a CRAL-TRIO motif common to proteins that bind small lipophilic molecules. Mutations in this gene are associated with cerebellar ataxia, Cayman type.
- Molecular Weight
- 42 kDa
-